Notable healthcare headlines for the week: J&J, Pfizer, and Novo Nordisk in focus
Seeking Alpha News (Sun, 28-Dec 9:05 AM ET)
3 Best ETFs to Invest In, According to AI Analyst, 12/26/2025
TipRanks (Fri, 26-Dec 6:36 AM ET)
Business Wire (Fri, 19-Dec 2:39 PM ET)
Bullish On MRK? You Might Want To Consider This Credit Put Spread Expiring in 9 Days
Market Chameleon (Fri, 19-Dec 8:10 AM ET)
Business Wire (Wed, 17-Dec 6:45 AM ET)
Business Wire (Fri, 12-Dec 8:45 AM ET)
PRNewswire (Tue, 9-Dec 8:52 AM ET)
Globe Newswire (Tue, 9-Dec 7:17 AM ET)
Business Wire (Thu, 4-Dec 12:05 PM ET)
Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
Globe Newswire (Tue, 2-Dec 8:30 AM ET)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Merck Common (New) trades on the NYSE stock market under the symbol MRK.
As of December 30, 2025, MRK stock price declined to $106.06 with 5,920,773 million shares trading.
MRK has a beta of 0.48, meaning it tends to be less sensitive to market movements. MRK has a correlation of 0.06 to the broad based SPY ETF.
MRK has a market cap of $263.24 billion. This is considered a Mega Cap stock.
Last quarter Merck Common (New) reported $17 billion in Revenue and $2.58 earnings per share. This beat revenue expectation by $265 million and exceeded earnings estimates by $.23.
In the last 3 years, MRK traded as high as $134.63 and as low as $73.31.
The top ETF exchange traded funds that MRK belongs to (by Net Assets): VTI, VOO, IVV, SPY, SCHD.
MRK has underperformed the market in the last year with a return of +9.7%, while SPY returned +16.7%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in MRK shares. However, MRK has outperformed the market in the last 3 month and 2 week periods, returning +36.1% and +5.8%, while SPY returned +3.8% and +1.2%, respectively. This indicates MRK has been having a stronger performance recently.
MRK support price is $104.81 and resistance is $108.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MRK shares will trade within this expected range on the day.
